Cannabis Leaf is Now Apotheca Biosciences (PCFP), Company’s Products and R & D Focuses on Opioid Crisis, a National Public Health Emergency
SAINT PETERSBURG, FL, Sept. 04, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE - Apotheca Biosciences (OTC PINK: PCFP), a developer of cutting-edge medical products, nutraceuticals, drug formulations and cannabis delivery technologies for the healthcare and consumer care industry announces the completion of its name change and filing of its Super 8K (Form 10 like) with the Security & Exchange Commission.
On March 6, 2018, An Agreement for Plan of Merger was entered into by Cannabis Leaf Incorporated, a Nevada Corporation, and Apotheca Biosciences, Inc., a Nevada Corporation. Such Agreement resulted in the merger of Apotheca Biosciences into Cannabis Leaf with the Corporation to survive as Cannabis Leaf (Apotheca Biosciences with name change).
The Board of Directors hence approved a change of its corporate name to Apotheca Biosciences, Inc. effective on August 1, 2018. The Board approved the name change in connection with the Company’s current business focus. In accordance with the Nevada Revised Statutes, Company changed its name at the effective August 2, 2018. This action was approved by the company’s Board of Directors on August 1, 2018 and no consent of Company’s stockholders was required under Nevada law. Our submission with the requisite documents and other information to the Financial Information Regulatory Association, Inc. (“FINRA”) to process the name change was approved on August 23, 2018. Trading symbol will stay the same as PCFP.
CUSIP number for our common stock which trades on the OTC PINK of the OTC Markets, Inc. will change as a result of the name change. The new CUSIP number will be 03836L 107.
There will be no mandatory exchange of stock certificates. Following the name change, the share certificates which reflect our prior name will continue to be valid. Certificates reflecting the new corporate name will be issued in due course as old share certificates are tendered for exchange or transfer to our transfer agent, Action Stock Transfer.
Apotheca Biosciences is developing cutting-edge medical products, nutraceuticals, drug formulations and delivery technologies for the healthcare and consumer care industry. Their pipeline of products includes, transdermal, sublingual, and nasal delivery technologies for precise and controlled dosing of cannabinoids. The company has developed three core platform technologies; CannaRAPID™, CannaNASAL™, and CannaDERME™, focused on precise dosing and controlled release of cannabinoid compounds for patients.
Company’s new exciting product called Epione-neck-Works, Wearable Wellness Necklace for Pain Relief. Epione is designed as a convenient and comfortable wearable neck device for EFFECTIVE medicinal transdermal delivery through the blood-brain barrier. Company is in final stage of development of the medical device.
Apotheca Biosciences is a pioneering biotech company with an emphasis in research and development in addition to the creation of high-grade nutraceuticals and pharma grade formulations. Apothecia’s’ goal is to lay the groundwork and continue research of cannabinoid receptiveness in patients and create nutraceuticals that reflects their research. Company’s 2018 R & D goals focused on products and technologies to address opioid crisis. The Company will also begin working with prominent universities across the globe to facilitate research studies on Opioid alternatives.
Opioid Crisis, a National Public Health Emergency - House approves massive opioids legislation
According to CNN, The House of Representatives passed the most expansive legislation Congress has taken to date to address the opioid crisis, approving a bipartisan package that combines 58 bills passed in the last two weeks.
Provisions in the final package address a wide range of issues related to the crisis that is wreaking havoc across the country, such as expanding access to treatment and recovery services, coming up with opioid alternatives for pain treatment, intercepting illegal opioids at mail facilities and combating use of fentanyl. In a time of sharp partisan divides and vitriol, the 396-14 bipartisan vote underscored the reach and scope of the crisis on Capitol Hill, where lawmakers and staff say the issue has become one of, if not the, top issues they hear about from constituents in their states and districts.
With the crisis continuing to see widespread deaths, opioids are an issue that has touched most, if not all, in the states, cities and towns represented on Capitol Hill. During 2016, there were more than 63,600 overdose deaths in the United States, including 42,249 that involved an opioid, according to the Centers for Disease Control. That’s an average of 115 opioid overdose deaths each day.
The bill, titled the Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act, builds onto other efforts by Congress in recent years to tackle the epidemic, including $4 billion in funding earlier this year in a large spending bill. In 2016, the House passed the Comprehensive Addiction and Recovery Act and the 21st Century Cures Act.
Since 1999, the rate of overdose deaths involving opioids nearly quadrupled, and over 165,000 people have died from prescription opioid overdoses. Prescription pain medication deaths remain far too high, and in 2014, the most recent year on record, there was a sharp increase in heroin-involved deaths and an increase in deaths involving synthetic opioids such as fentanyl. Prevention, treatment, and research to rapidly tackle and reverse opioid overdoses are critical to fighting this epidemic.
Early data coming out of states where marijuana laws have been passed suggest that even as conventionally used, marijuana may be playing a role in offsetting the opioid addiction epidemic. Studies have shown that phytocannabinoids like cannabidiol have promising results in opioid withdrawal symptoms and heroin-seeking behavior.
Our studies have shown that cannabidiol can have promising improvements in opioid withdrawal symptoms by attenuating the rewarding effects of opioids. There is at least partial evidence that cannabinoid compounds can relieve from depression. Apotheca Biosciences will partner with opioid addiction centers and clinical practitioners to conduct studies on the use of RAPID for opioid addiction.
If you would like more information on Apotheca’s products, please visit: www.apothecabiosciences.com/products-pipeline.
About Apotheca Biosciences Inc.
Apotheca is a developer of cutting-edge medical products, nutraceuticals, formulation and delivery technologies for the healthcare and consumer care industry. Its pipeline of products includes, transdermal, sublingual, and nasal delivery technologies for precise and controlled dosing of cannabinoids. Apotheca believes that it can deliver meaningful benefits using its technologies to the world’s aging population.
To request further information about Apotheca, please email firstname.lastname@example.org, or visit its website at http://www.apothecabiosciences.com/, or visit it on FB @apotheca and Twitter @apotheca
This press release may contain forward-looking statements covered within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to, among other things, plans and timing for the introduction or enhancement of our services and products, statements about future market conditions, supply and demand conditions, and other expectations, intentions and plans contained in this press release that are not historical fact and involve risks and uncertainties. Our expectations regarding future revenues depend upon our ability to develop and supply products and services that we may not produce today and that meet defined specifications. When used in this press release, the words “plan,” “expect,” “believe,” and similar expressions generally identify forward-looking statements. These statements reflect our current expectations. They are subject to a number of risks and uncertainties, including, but not limited to, changes in technology and changes in pervasive markets. This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approval for anticipated actions.
Contact: Media Contact: (727) 228-3994 Apotheca Biosciences http://www.apothecabiosciences.com email@example.com Twitter - @apotheca Facebook – apotheca Telegram- apotheca